Uterine Leiomyosarcoma with FN1-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib

Uterine leiomyosarcoma (LMS) is a rare malignant neoplasm of the female genital tract poorly responsive to conventional chemotherapy and radiotherapy, with an overall poor prognosis. Pazopanib is at the moment the only FDA-approved targeted molecular therapy for uterine LMS, given the exceedingly ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Testa, Stefano, Million, Lynn, Longacre, Teri, Bui, Nam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255722/
https://www.ncbi.nlm.nih.gov/pubmed/34248545
http://dx.doi.org/10.1159/000516758

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255722/
https://www.ncbi.nlm.nih.gov/pubmed/34248545
http://dx.doi.org/10.1159/000516758

Ejemplares similares